New4med

Executive Summary

New4med, founded in 2020 and headquartered in Munich, Germany, is a medical technology company at the intersection of medical devices and drug delivery. The company focuses on developing innovative, integrated systems to enhance treatment efficacy and improve patient outcomes. By combining device and pharmaceutical expertise, New4med aims to create synergistic solutions that address unmet clinical needs, particularly in areas where conventional drug delivery is suboptimal. As a relatively young company, New4med is in the early stages of product development and validation, with no disclosed funding rounds or clinical milestones to date. The company operates in a competitive landscape but differentiates itself through a cross-disciplinary approach that leverages both engineering and pharmacology. Success will depend on securing regulatory approvals, clinical evidence generation, and strategic partnerships to bring its pipeline to market.

Upcoming Catalysts (preview)

• Q4 2026Initiation of first clinical trial for lead candidate40% success
• 2027CE Mark submission or designation for core product30% success
• 2026Strategic partnership with pharmaceutical company for drug-device combination35% success